CO6180441A2 - Inhibidores nucleosidos del hcv - Google Patents

Inhibidores nucleosidos del hcv

Info

Publication number
CO6180441A2
CO6180441A2 CO09033094A CO09033094A CO6180441A2 CO 6180441 A2 CO6180441 A2 CO 6180441A2 CO 09033094 A CO09033094 A CO 09033094A CO 09033094 A CO09033094 A CO 09033094A CO 6180441 A2 CO6180441 A2 CO 6180441A2
Authority
CO
Colombia
Prior art keywords
hydrogen
compound according
cor4
phenyl
group
Prior art date
Application number
CO09033094A
Other languages
English (en)
Inventor
Nils-Gunnar Johansson
Genadiy Kalayanov
Joseph Armstrong Martin
David Bernard Smith
Anna Winqvist
Original Assignee
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir Ab filed Critical Medivir Ab
Publication of CO6180441A2 publication Critical patent/CO6180441A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/073Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/191Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/193Colony stimulating factors [CSF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

1.- Un compuesto de fórmula Idonde: R1, R2 y R3 se seleccionan en forma independiente entre el grupo que consiste en hidrógeno, COR4, C(=O)OR4 y C(=O)CHR5NHR6; o R1 y R3 son H y R2 es el éster monofosfato, difosfato o trifosfato; R4 se selecciona en forma independiente entre el grupo que consiste en (a) C1-18 alquilo lineal o ramificado, (b) C1-18 haloalquilo, (c) C3-8 cicloalquilo, (d) C1-10 heteroalquilo y (e) fenilo donde dicho fenilo está opcionalmente sustituido con entre uno y tres grupos seleccionados en forma independiente entre C1-3 alquilo, C1-3 alcoxi, halógeno, ciano o nitro; R5 es hidrógeno, C1-10 alquilo, fenilo o C1-3 fenilalquilo donde dicho fenilo está opcionalmente sustituido con entre uno y tres grupos seleccionados en forma independiente entre el grupo que consiste en halógeno, hidroxi, C1-3 alcoxi, C1-3 alquilo, ciano y nitro; R6 es hidrógeno o C1-6 alcoxi; o, sales de adición ácida del mismo. 2.- Un compuesto de acuerdo con la reivindicación 1 en donde R1, R2 y R3 son en cada caso hidrógeno. 3.- Un compuesto de acuerdo con la reivindicación 1 en donde R1, R2 y R3 son cada uno en forma independiente hidrógeno, OCR4 o C(=O)OR4. 4.- Un compuesto de acuerdo con la reivindicación 3 en donde R4 es C1-10 alquilo lineal o ramificado. 5.- Un compuesto de acuerdo con la reivindicación 1 en donde R1 es hidrógeno y R2 y R3 son COR4. 6.- Un compuesto de acuerdo con la reivindicación 1 en donde R1 es hidrógeno, R2 y R3 son COR4 y R4 es alquilo lineal o ramificado; o una sal farmacéuticamente aceptable del mismo. 7.- Un compuesto de acuerdo con la reivindicación 1 en donde R1 y R3 son hidrógeno R2 se selecciona entre el grupo que consiste en COR4, C(=O)OR4 y COCH(R5)NHR6. 8.- Un compuesto de acuerdo con la reivindicación 7 en donde R2 es COCH(R5)NHR6, R5 es iso-propilo, iso-butilo o sec-butilo y R6 es hidrógeno. 9.- Un compuesto de acuerdo con la reivindicación 8 en donde R5 tiene la estereoquímica de un L-aminoácido. 10.- Un compuesto de acuerdo con la reivindicación 7, en donde R2 es OCR4.
CO09033094A 2006-10-10 2009-03-31 Inhibidores nucleosidos del hcv CO6180441A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85092606P 2006-10-10 2006-10-10

Publications (1)

Publication Number Publication Date
CO6180441A2 true CO6180441A2 (es) 2010-07-19

Family

ID=38925483

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09033094A CO6180441A2 (es) 2006-10-10 2009-03-31 Inhibidores nucleosidos del hcv

Country Status (32)

Country Link
US (4) US7666856B2 (es)
EP (2) EP2361922B1 (es)
JP (2) JP2010505902A (es)
KR (1) KR20090078347A (es)
CN (2) CN101573370B (es)
AP (1) AP2009004812A0 (es)
AT (1) ATE493428T1 (es)
AU (1) AU2007306405A1 (es)
BR (1) BRPI0719258A2 (es)
CA (1) CA2665049C (es)
CO (1) CO6180441A2 (es)
CR (1) CR10789A (es)
CY (1) CY1111342T1 (es)
DE (1) DE602007011658D1 (es)
DK (1) DK2084175T3 (es)
EA (1) EA018935B1 (es)
ES (2) ES2358853T3 (es)
GT (1) GT200900069A (es)
HK (2) HK1137459A1 (es)
HN (1) HN2009000614A (es)
HR (1) HRP20110193T1 (es)
IL (1) IL197907A0 (es)
MX (1) MX2009003452A (es)
MY (1) MY145314A (es)
NO (1) NO20091834L (es)
NZ (1) NZ575889A (es)
PL (2) PL2361922T3 (es)
PT (1) PT2084175E (es)
RS (1) RS51643B (es)
SI (1) SI2084175T1 (es)
WO (1) WO2008043704A1 (es)
ZA (1) ZA200902496B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2009004812A0 (en) * 2006-10-10 2009-04-30 Medivir Ab HCV nucleoside inhibitor
CN100532388C (zh) * 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
AR072428A1 (es) 2008-07-01 2010-08-25 Medivir Ab Derivados de pirimidin nucleotidos inhibidores de polimerasas del virus de la hepatitis c (vhc), composiciones farmaceuticas que los contienen y metodo para prepararlos.
TWI454476B (zh) 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作c型肝炎病毒抑制劑之巨環吲哚衍生物
EP2166016A1 (en) 2008-09-18 2010-03-24 Centocor Ortho Biotech Products L.P. Phosphoramidate Derivatives of Nucleosides
TW201023858A (en) * 2008-09-18 2010-07-01 Ortho Mcneil Janssen Pharm Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside
PA8852101A1 (es) 2008-12-08 2010-07-27 Medivir Ab Nucleótidos uracil ciclopropílicos
DE102009028015A1 (de) * 2009-07-24 2011-01-27 Virologik Gmbh Mittel zur Behandlung von Hepatitis C-Infektionen
US8552021B2 (en) 2009-09-29 2013-10-08 Janssen Products, L.P. Phosphoramidate derivatives of nucleosides
KR20130057990A (ko) 2010-04-13 2013-06-03 얀센 파마슈티칼즈, 인코포레이티드 마크로사이클릭 hcv 저해제, 비뉴클레오시드 및 뉴클레오시드의 배합물
PE20140608A1 (es) 2010-09-22 2014-06-12 Alios Biopharma Inc Analogos de nucleotidos sustituidos
WO2012040124A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
WO2012154321A1 (en) 2011-03-31 2012-11-15 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2013039920A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
EP2768838A1 (en) 2011-10-14 2014-08-27 IDENIX Pharmaceuticals, Inc. Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
EP2794630A4 (en) 2011-12-22 2015-04-01 Alios Biopharma Inc SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE
NZ631601A (en) 2012-03-21 2016-06-24 Alios Biopharma Inc Solid forms of a thiophosphoramidate nucleotide prodrug
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
EP2852605B1 (en) 2012-05-22 2018-01-31 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphate prodrugs for hcv infection
AP3913A (en) 2012-05-22 2016-11-26 Idenix Pharamaceuticals Inc D-amino acid compounds for liver disease
UY34824A (es) 2012-05-25 2013-11-29 Janssen R & D Ireland Nucleósidos de espirooxetano de uracilo
EP2900682A1 (en) 2012-09-27 2015-08-05 IDENIX Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
PE20151318A1 (es) 2012-10-08 2015-10-03 Idenix Pharmaceuticals Inc Analogos de 2'-cloro nucleosido para infeccion por vhc
US10723754B2 (en) 2012-10-22 2020-07-28 Idenix Pharmaceuticals Llc 2′,4′-bridged nucleosides for HCV infection
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
KR102327888B1 (ko) * 2012-12-21 2021-11-17 얀센 바이오파마, 인코퍼레이트. 치환된 뉴클레오사이드, 뉴클레오타이드 및 그것의 유사체
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
WO2014160484A1 (en) 2013-03-13 2014-10-02 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
US9187515B2 (en) 2013-04-01 2015-11-17 Idenix Pharmaceuticals Llc 2′,4′-fluoro nucleosides for the treatment of HCV
EP3004130B1 (en) 2013-06-05 2019-08-07 Idenix Pharmaceuticals LLC. 1',4'-thio nucleosides for the treatment of hcv
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
UA117375C2 (uk) * 2013-09-04 2018-07-25 Медівір Аб Інгібітори полімерази hcv
EP3131914B1 (en) 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6339752A (ja) 1986-08-02 1988-02-20 Kawada Tekko Kk インデツクス装置
SE8701605D0 (sv) 1987-04-16 1987-04-16 Astra Ab Novel medicinal compounds
DE3715666A1 (de) 1987-05-11 1988-11-24 Kodak Ag Kassettenentlade- und beladegeraet
GB8712115D0 (en) 1987-05-22 1987-06-24 Hoffmann La Roche Pyrimidine derivatives
US5246924A (en) * 1987-09-03 1993-09-21 Sloan-Kettering Institute For Cancer Research Method for treating hepatitis B virus infections using 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil
SE8802173D0 (sv) 1988-06-10 1988-06-10 Astra Ab Pyrimidine derivatives
SE8802687D0 (sv) 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
HUT51643A (en) * 1988-11-21 1990-05-28 Syntex Inc Process for producing antiviral agents and pharmaceutical compositions comprising same as active ingredient
US5034518A (en) * 1989-05-23 1991-07-23 Southern Research Institute 2-fluoro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl) adenine nucleosides
WO1991015470A1 (en) 1990-03-30 1991-10-17 Eastman Kodak Company Alcohol-ester separation by reaction with acetate
AU7623991A (en) * 1990-05-17 1991-11-21 Syntex (U.S.A.) Inc. Antiviral agents
IT1249732B (it) 1991-11-26 1995-03-09 Angeletti P Ist Richerche Bio Oligonucleotidi antisenso.
US5418151A (en) 1992-08-07 1995-05-23 Genencor International, Inc. Regio-selective process for resolution of carbohydrate monoesters
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
BR9908270A (pt) * 1998-02-25 2004-06-29 Univ Emory 2-fluoro-nucleosìdeos, composições farmacêuticas e seus usos
AU756627B2 (en) 1998-07-27 2003-01-16 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Diketoacid-derivatives as inhibitors of polymerases
AU743411B2 (en) 1998-08-21 2002-01-24 Viropharma Incorporated Compounds, compositions and methods for treating or preventing viral infections and associated diseases
US6440985B1 (en) 1998-09-04 2002-08-27 Viropharma Incorporated Methods for treating viral infections
CN1324212A (zh) 1998-09-25 2001-11-28 维洛药品公司 治疗或预防病毒感染及有关疾病的方法
DE60005502T2 (de) 1999-05-12 2004-06-24 Yamasa Corp., Choshi 4'-c-ethynyl-purin-nukleoside
US6566365B1 (en) 1999-11-04 2003-05-20 Biochem Pharma Inc. Method for the treatment of Flaviviridea viral infection using nucleoside analogues
WO2001047833A1 (fr) 1999-12-24 2001-07-05 Asahi Glass Company, Limited Filtre au nitrure de silicium et procede de fabrication correspondant
WO2001077091A2 (en) 2000-04-05 2001-10-18 Tularik Inc. Ns5b hcv polymerase inhibitors
EP1292310A1 (en) 2000-05-10 2003-03-19 SmithKline Beecham Corporation Novel anti-infectives
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
NZ547204A (en) 2000-05-26 2008-01-31 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
WO2002005787A1 (fr) 2000-07-17 2002-01-24 Takeda Chemical Industries, Ltd. Fabrication pour produits lyophilises
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
MXPA03006514A (es) 2001-01-22 2004-12-02 Merck & Co Inc Derivados de nucleosidos como inhibidores de polimerasa de acido ribonucleico viral dependiente de acido ribonucleico.
US6677120B2 (en) 2001-03-30 2004-01-13 Isis Pharmaceuticals, Inc. Building blocks for the solution phase synthesis of oligonucleotides
KR100798579B1 (ko) 2001-03-31 2008-01-28 동화약품공업주식회사 신규의 메톡시-1,3,5-트리아진 유도체 및 그를 포함하는약학적 조성물
AR036081A1 (es) 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
ATE438637T1 (de) 2001-06-11 2009-08-15 Virochem Pharma Inc Thiophenderivate als antivirale mittel gegen flavivirus-infektion
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
US6841566B2 (en) 2001-07-20 2005-01-11 Boehringer Ingelheim, Ltd. Viral polymerase inhibitors
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US6899700B2 (en) 2001-08-29 2005-05-31 Kimberly-Clark Worldwide, Inc. Therapeutic agent delivery tampon
WO2003026675A1 (en) 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
AU2002330154A1 (en) 2001-09-28 2003-04-07 Centre National De La Recherche Scientifique Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
WO2003037262A2 (en) 2001-10-29 2003-05-08 Smithkline Beecham Corporation Novel anit-infectives
AU2002365198A1 (en) 2001-10-30 2003-07-30 Smithkline Beecham Corporation Novel anti-infectives
AU2002351077A1 (en) 2001-11-05 2003-05-19 Exiqon A/S Oligonucleotides modified with novel alpha-l-rna analogues
WO2003052248A1 (es) 2001-12-18 2003-06-26 Fernandez Del Castillo Y Simon Multipiston en columna
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
WO2003099801A1 (en) 2002-05-24 2003-12-04 Smithkline Beecham Corporation Novel anti-infectives
WO2004002999A2 (en) 2002-06-28 2004-01-08 Idenix (Cayman) Limited Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
AU2003248748A1 (en) * 2002-06-28 2004-01-19 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
PL374792A1 (en) 2002-06-28 2005-10-31 Idenix (Cayman) Limited 2' and 3'-nucleoside prodrugs for treating flaviviridae infections
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
EP2361913A1 (en) 2002-11-01 2011-08-31 Abbott Laboratories Anti-infective agents
NO319194B1 (no) 2002-11-14 2005-06-27 Pronova Biocare As Lipase-katalysert forestringsfremgangsmate av marine oljer
KR20050088079A (ko) 2002-11-15 2005-09-01 이데닉스 (케이만) 리미티드 2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
TWI294882B (en) * 2002-12-09 2008-03-21 Hoffmann La Roche Anhydrous crystalline azido cytosine hemisulfate derivative
WO2004052313A2 (en) 2002-12-11 2004-06-24 Smithkline Beecham Corporation Anti-infectives
WO2004052312A2 (en) 2002-12-11 2004-06-24 Smithkline Beecham Corporation Anti-infectives
AU2003297235A1 (en) 2002-12-17 2004-07-22 Smithkline Beecham Corporation Anti-infectives
US20040259934A1 (en) 2003-05-01 2004-12-23 Olsen David B. Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
EP1644395B1 (en) 2003-06-19 2006-11-22 F. Hoffmann-La Roche Ag Processes for preparing 4'azido nucleoside derivatives
US7125845B2 (en) 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
WO2005019191A2 (en) 2003-08-25 2005-03-03 Abbott Laboratories 1, 1-dioxido-4h-1,2,4-benzothiadiazine derivate und verwandte verbindungen als inhibitoren der hcv polymerase zur behandlung von hepatitis c
US7642235B2 (en) 2003-09-22 2010-01-05 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
ATE461209T1 (de) 2004-01-30 2010-04-15 Medivir Ab Hcv ns-3 serine protease inhibitoren
WO2006021340A1 (en) 2004-08-23 2006-03-02 F.Hoffmann-La Roche Ag Heterocyclic antiviral compounds
CA2577526A1 (en) * 2004-08-23 2006-03-02 Joseph Armstrong Martin Antiviral 4'-azido-nucleosides
AP2009004812A0 (en) * 2006-10-10 2009-04-30 Medivir Ab HCV nucleoside inhibitor

Also Published As

Publication number Publication date
ATE493428T1 (de) 2011-01-15
RS51643B (en) 2011-10-31
ES2392948T3 (es) 2012-12-17
PT2084175E (pt) 2011-04-01
CN101979397A (zh) 2011-02-23
ES2358853T3 (es) 2011-05-16
DK2084175T3 (da) 2011-04-18
GT200900069A (es) 2009-11-06
JP2010505902A (ja) 2010-02-25
MX2009003452A (es) 2009-04-14
EP2084175B1 (en) 2010-12-29
EA200970358A1 (ru) 2009-12-30
DE602007011658D1 (de) 2011-02-10
EP2084175A1 (en) 2009-08-05
EA018935B1 (ru) 2013-11-29
BRPI0719258A2 (pt) 2014-04-29
JP2011246485A (ja) 2011-12-08
HK1154247A1 (en) 2012-04-13
CR10789A (es) 2009-09-14
NO20091834L (no) 2009-05-11
CN101573370B (zh) 2013-09-11
ZA200902496B (en) 2010-06-30
US8158779B2 (en) 2012-04-17
US7825239B2 (en) 2010-11-02
PL2084175T3 (pl) 2011-06-30
CY1111342T1 (el) 2015-08-05
US20110172410A1 (en) 2011-07-14
MY145314A (en) 2012-01-13
US7666856B2 (en) 2010-02-23
US20100130735A1 (en) 2010-05-27
US20080152621A1 (en) 2008-06-26
EP2361922A1 (en) 2011-08-31
AU2007306405A1 (en) 2008-04-17
HN2009000614A (es) 2011-07-11
US7935681B2 (en) 2011-05-03
US20110015148A1 (en) 2011-01-20
AP2009004812A0 (en) 2009-04-30
CN101979397B (zh) 2013-11-06
EP2361922B1 (en) 2012-08-22
IL197907A0 (en) 2009-12-24
PL2361922T3 (pl) 2013-01-31
CN101573370A (zh) 2009-11-04
HK1137459A1 (en) 2010-07-30
CA2665049A1 (en) 2008-04-17
SI2084175T1 (sl) 2011-05-31
KR20090078347A (ko) 2009-07-17
NZ575889A (en) 2011-09-30
CA2665049C (en) 2012-12-04
WO2008043704A1 (en) 2008-04-17
HRP20110193T1 (hr) 2011-05-31

Similar Documents

Publication Publication Date Title
CO6180441A2 (es) Inhibidores nucleosidos del hcv
GT200800170A (es) Compuestos de n-formil-hidroxilamina
GT200800258A (es) Compuestos de pirrolo-pirimidina y sus usos
AR062797A1 (es) Derivados de piperidina como inhibidores de renina, composiciones farmaceuticas.
UY30603A1 (es) Derivados de 2-aril-6-fenil-imidazo[1, 2-a]piridinas, su preparacion y su aplicacion en terapéutica
AR056686A1 (es) Derivados de diacilindazol como inhibidores de lipasas y fosfolipasas
AR083058A1 (es) Compuestos de estructura de imidazotriazinona
MX357131B (es) Composicion para el control de plagas que incluye un derivado de iminopiridina novedoso.
UA101328C2 (uk) Похідні 6-триазолпіридинсульфанілбензотіазолу і -бензімідазолу, спосіб їх одержання (варіанти), застосування їх як лікарських засобів, фармацевтична композиціїя та застосування як інгібіторів met
UY30004A1 (es) Metodos y kits para dosificar nucléosidos antivirales beta-d-2´, 3´-didehidro-2´, 3´- dideoxi-5-fluorocitidina
AR074504A1 (es) Nucleotidos uracil ciclopropilicos
ECSP088965A (es) Derivados de 2-tioxantina que actúan como inhibidores de la mpo
AR088625A1 (es) Derivados de aril-quinolina
EA201600241A1 (ru) Замещенные (2r,3r,5r)-3-гидрокси-(5-пиримидин-1-ил)тетрагидрофуран-2-илметил арил фосфорамидаты
AR064424A1 (es) Derivados sustituidos de 1-oxo-ftalazinas y 1-oxo-pirido-piridazinas,composiciones farmaceuticas que los contienen y usos para prevenir y/o tratar enfermedades inflamatorias y alergicas del tracto respiratorio.
AR053345A1 (es) Compuesto de 1,2,4 triazolo-5-ona como inhibidores de la transcriptasa inversa
AR054266A1 (es) Indoles sustituidos con piperidina
DE602006000226D1 (de) Verfahren zur Herstellung von Adapalene
ATE547100T1 (de) Leberfibroseinhibitor
ATE514702T1 (de) Verfahren zur herstellung von clopidogrel und dabei verwendete zwischenprodukte
HN2010001700A (es) Procedimiento de preparacion de combretastatina
CO6270185A2 (es) Derivados de isotiazol y pirazol como fungicidas
SG154418A1 (en) Granular composition and production thereof
ES2546833T3 (es) Derivados de pirrolidina como antagonistas de receptores de NK-3
AR065724A1 (es) Macrolidos

Legal Events

Date Code Title Description
FC Application refused